TABLE 3.

PERCENT CHANGE IN NASAL PD AFTER AMILORIDE

Day of Study	Premature Stop Group: Gentamicin*	Premature Stop Group: Tobramycin†	Control Group: Gentamicin and Tobramycin
D01 “pre” values	40.20% (18.26)	45.26% (17.81)	42.06% (12.57)
Day 07 (D07–D01)	5.18 (15.82)	−0.31 (8.89)	−8.90 (13.71)
Day 14 (D14–D01)	−5.35 (18.62)	1.30 (13.70)	−5.33 (16.16)
Post-values (D28–D01)	1.24 (20.31)	4.01 (11.08)	−5.51 (15.61)

Definition of abbreviation: PD, potential difference.

Change in PD from pretreatment in premature stop subjects during gentamicin and tobramycin treatment, and in control subjects during treatment (with either aminoglycoside). Values in the “Day 01 pretreatment” row are the mean % change in PD after amiloride (± SD). Values below are changes from the Day 01 value (average values of both nostrils per subject). Day 07 and Day 14 are “on treatment.” Reduced changes in PD reflect improvements in CFTR function.

^*There is a significant group x day interaction for the averaged nostril results (P < 0.02, groups = control subjects and premature stop subjects on gentamicin). None of the individual pair-wise comparisons are significant.

^†There is significant difference between groups for the averaged nostril results (P < 0.05, groups = control subjects and premature stop subjects on tobramycin). None of the individual pair-wise comparisons are significant.